Clinical trials: Crohn Disease of Intestine
IBD, Inflammatory Bowel Diseases
The Assessment of Infrared Treatment for Crohn's Disease
The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients. The main questions it aims to answer are: 1.
- Conditions
- IBD, Inflammatory Bowel Diseases, Crohn Disease
- Trial name
- NCT06146816
- Testing
- High level photobiomodulation treatment in the infrared (IR) range., Medium level photobiomodulation treatment in the far infrared (IR) range, Low level photobiomodulation treatment in the far infrared (IR) range
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Shmuel Kivity, MD
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Irritable Bowel Syndrome, Cyclical Vomiting Syndrome
Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.
The structural/RSN study involves Structural and Resting State Neuroimaging. The purpose of Structural Neuroimaging is to use MRI technology to identify cortical and white matter morphometric differences between patients with…
- Conditions
- Irritable Bowel Syndrome, Cyclical Vomiting Syndrome, Ulcerative Colitis, Vulvodynia
- Trial name
- MMI (NCT01517516)
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Crohn's Disease
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).
- Trial name
- NCT01393626
- Testing
- CP-690,550
- Where
- 140 sites in United States, Australia and 16 more
- Volunteers
- 280 people
- Sponsor
- Pfizer
Crohn Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term…
- Trial name
- DUET ENCORE-CD (NCT07577843)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 252 sites in United States, Argentina and 28 more
- Volunteers
- 460 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases, Ulcerative Colitis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- Trial name
- CONNECT-IBD (NCT02539368)
- Testing
- CT-P13, Remicade
- Where
- 140 sites in Belgium, Czechia and 11 more
- Volunteers
- 2,565 people
- Sponsor
- Pfizer
Inflammatory Bowel Diseases (IBD), Crohns Disease
Development and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS)
Children with inflammatory bowel disease (IBD) including both Crohn's disease (CD) and ulcerative colitis (UC) can be at high risk of developing malnutrition due to the nature of their condition.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohns Disease, Ulcerative Colitis (UC)
- Trial name
- PIBD-NUTS (NCT06723418)
- Testing
- Malnutriton Screening Tool (PYMS)
- Where
- 8 sites in Austria, Croatia and 4 more
- Volunteers
- 2,000 people
- Sponsor
- University of Glasgow
Crohn Disease
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
- Trial name
- NCT00206713
- Testing
- Sargramostim (Leukine)
- Where
- 7 sites in United States
- Volunteers
- 264 people
- Sponsor
- Genzyme, a Sanofi Company
Colitis Ulcerative, Crohn's Disease
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week…
- Trial name
- NCT07222189
- Testing
- balinatunfib
- Where
- 10 sites in United States, Argentina and 5 more
- Volunteers
- 7 people
- Sponsor
- Sanofi
Crohn Disease, Ulcerative Colitis
Impact of Prebiotics in Ulcerative Colitis
The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity.
- Trial name
- NCT06495658
- Testing
- Prebiotic
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of California, Los Angeles
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240108
- Testing
- Rifaximin EIR
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Bausch Health Americas, Inc.
Crohn's Disease, Inflammatory Bowel Disease
Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy
Crohn's disease is an inflammatory disorder that can affect any part of the gastrointestinal (GI) tract. Some patients still experience persistent diarrhea or other symptoms such as abdominal pain even when their Crohn's disease…
- Trial name
- REACT (NCT04456517)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University Medical Center
Crohn's Disease
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called…
- Trial name
- VICTRIVA (NCT06227910)
- Testing
- Vedolizumab, Upadacitinib
- Where
- 138 sites in United States, Austria and 24 more
- Volunteers
- 396 people
- Sponsor
- Takeda
Ulcerative Colitis, Crohn Disease
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in…
- Trial name
- QUOTIENT (NCT05230173)
- Testing
- Pragmatic
- Where
- 24 sites in United States
- Volunteers
- 216 people
- Sponsor
- Mayo Clinic
Crohn Disease
Validation of an IUS Activity Index
The primary objective of this study is to prospectively validate a novel intestinal ultrasound (IUS) Crohn's disease (CD) activity index and component items, correlating CD activity and responsiveness to therapy as evaluated by…
- Trial name
- USE-IT (NCT05407350)
- Testing
- Ultrasound, Colonoscopy, MRE
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- International Bowel Ultrasound Group e.V.
Chronic Mesenteric Ischemia, Median Arcuate Ligament Syndrome
Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome…
- Conditions
- Chronic Mesenteric Ischemia, Median Arcuate Ligament Syndrome, Crohn Disease, Cholelithiasis
- Trial name
- NCT06468774
- Testing
- Laparoscopic surgery
- Where
- Norway
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Crohn Disease (CD)
Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.
Ustekinumab (UST) is a novel biologic agent that targets and binds to Interleukin-12 (IL-12) and Interleukin-23 (IL-23), and is approved for inducing and maintaining remission in Crohn Disease(CD).
- Trial name
- USE-OPT CD (NCT06912815)
- Testing
- ustekinumab and semi enteral nutrition, Exclusive enteral nutrition
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Xiang Gao
Crohn's Disease
Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients
We study if the administration of intralesional Adalimumab (directly injected in the stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared with placebo in patients with Crohn's disease who…
- Trial name
- NCT01986127
- Testing
- Adalimumab
- Where
- 13 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Sara Varea
Crohn's Disease
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection…
- Trial name
- NCT01714726
- Testing
- MEDI2070
- Where
- 80 sites in United States, Canada and 7 more
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Inflammatory Bowel Disease, Crohn Disease
Vascular Dysfunction in Paediatric IBD
Inflammatory Bowel Diseases (IBD) is a group of relapsing and remitting gut inflammatory conditions acquired due to genetic susceptibility and/or environmental triggers.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT02161640
- Where
- United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.